AnaptysBio Q4 EPS Rises to $1.58, Revenues Jump 151% to $108M
AnaptysBio delivered Q4 EPS of $1.58, beating estimates of $0.89 by 78.5% and reversing a year-ago loss of $0.72 per share. Revenue rose 151% year-over-year to $108.25 million, topping forecasts by 28.5% after four straight quarters of estimate beat.
1. Q4 Earnings Beat
AnaptysBio reported adjusted EPS of $1.58 for Q4, surpassing estimates of $0.89 by 78.5% and reversing a year-ago loss of $0.72 per share. This marks the fourth consecutive quarter of EPS outperformance.
2. Strong Revenue Expansion
Revenue in Q4 rose 151% to $108.25 million from $43.11 million a year earlier, exceeding consensus by 28.47%. The company has now topped revenue estimates in each of the past four quarters.
3. Cautious Outlook and Estimate Trends
Consensus EPS forecasts stand at -$1.10 for the upcoming quarter and -$4.34 for the fiscal year, reflecting recent downward estimate revisions. The company holds a consensus sell rating, suggesting potential underperformance relative to market averages.